Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis

References

• Noris M Remuzzi G Atypical hemolytic-uremic syndrome N Engl J Med 2009 361 17 1676 1687 19846853
   PubMed Web of Science ®Google Scholar
• Warwicker P Goodship TH Donne RL Genetic studies into inherited and sporadic hemolytic uremic syndrome Kidney Int 1998 53 4 836 844 9551389
   PubMed Web of Science ®Google Scholar
• Medina PJ Sipols JM George JN Drug associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome Curr Opin Hematol 2001 8 5 286 293 11604563
   PubMed Web of Science ®Google Scholar
• George JN Terrell DR Vesely SK Kremer Hovinga JA Lämmle B Thrombotic microangiopathic syndromes associated with drugs, HIV infection, hematopoietic stem cell transplantation and cancer Presse Med 2012 41 3 Pt 2 e177 e188 22244728
   PubMedGoogle Scholar
• Zuber J Martinez F Droz D Oksenhendler E Legendre C Groupe D’étude Des Nephrologues D’ile-de-France (GENIF) Alpha-interferon-associated thrombotic microangiopathy: a clinicopathologic study of 8 patients and review of the literature Medicine (Baltimore) 2002 81 4 321 331 12169887
   PubMed Web of Science ®Google Scholar
• Aravindan A Yong J Killingsworth M Suranyi M Wong J Minimal change disease with interferon-beta therapy for relapsing remitting multiple sclerosis NDT Plus 2010 3 2 132 134
   Google Scholar
• Harvey M Rosenfeld D Davies D Hall BM Recombinant interferon alpha and hemolytic uremic syndrome: cause or coincidence? Am J Hematol 1994 46 2 152 153 8172186
   PubMed Web of Science ®Google Scholar
• Vaughan CJ Delanty N Hypertensive emergencies Lancet 2000 356 9227 411 417 10972386
   PubMed Web of Science ®Google Scholar
• Zhang B Xing C Yu X Sun B Zhao X Qian J Renal thrombotic microangiopathies induced by severe hypertension Hypertens Res 2008 31 3 479 483 18497467
   PubMed Web of Science ®Google Scholar
• Halevy D Radhakrishnan J Markowitz G Appel G Thrombotic microangiopathies Crit Care Clin 2002 18 2 309 320 12053836
   PubMed Web of Science ®Google Scholar
• Piette JC Papo T Potential role for antiphospholipid antibodies in renal thrombotic microangiopathy induced by interferon-alpha Nephrol Dial Transplant 1995 10 9 1781 8559510
   PubMed Web of Science ®Google Scholar
• IJdo JW Conti-Kelly AM Greco P Anti-phospholipid antibodies in patients with multiple sclerosis and MS-like illnesses: MS or APS? Lupus 1999 8 2 109 115 10192504
   PubMed Web of Science ®Google Scholar
• Malina M Roumenina LT Seeman T Genetics of hemolytic uremic syndromes Presse Med 2012 41 3 Pt 2 e105 e114 22265161
   PubMedGoogle Scholar
• Warwicker P Goodship TH Donne RL Genetic studies into inherited and sporadic hemolytic uremic syndrome Kidney Int 1998 53 4 836 844 9551389
   PubMed Web of Science ®Google Scholar
• Richards A Kemp EJ Liszewski MK Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome Proc Natl Acad Sci USA 2003 100 22 12966 12971 14566051
   PubMed Web of Science ®Google Scholar
• Fremeaux-Bacchi V Dragon-Durey MA Blouin J Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome J Med Genet 2004 41 6 e84 15173250
   PubMed Web of Science ®Google Scholar
• Moake JL Thrombotic microangiopathies N Engl J Med 2002 347 8 589 600 12192020
   PubMed Web of Science ®Google Scholar
• Ferrara N Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 2004 25 4 581 611 15294883
   PubMed Web of Science ®Google Scholar
• Sidky YA Borden EC Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses Cancer Res 1987 47 19 5155 5161 2441862
   PubMed Web of Science ®Google Scholar
• Aaronson DS Horvath CM A road map for those who don’t know JAK-STAT Science 2002 296 5573 1653 1655 12040185
   PubMed Web of Science ®Google Scholar
• Schrijvers BF Flyvbjerg A De Vriese AS The role of vascular endothelial growth factor (VEGF) in renal pathophysiology Kidney Int 2004 65 6 2003 2017 15149314
   PubMed Web of Science ®Google Scholar
• ema.europa.eu [homepage on the Internet] Summary of product characteristics of Rebif® [updated 2013 April 18] Available from: http://www.ema.europa.eu/ema/ Accessed June 26, 2013
   Google Scholar
• Hansen T New D Reeve R Donne R Stephens W Acute renal failure, systemic lupus erythematosus and thrombotic microangiopathy following treatment with beta-interferon for multiple sclerosis: case report and review of the literature NDT Plus 2009 2 6 466 468
   Google Scholar
• Crispin JC Diaz-Jouanen E Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis Lupus 2005 14 6 495 496 16038117
   PubMed Web of Science ®Google Scholar
• Ubara Y Hara S Takedatu H Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C Nephron 1998 80 1 107 108 9730725
   PubMed Web of Science ®Google Scholar
• Herrera WG Balizet LB Harberts SW Occurrence of a TTP-like syndrome in two women receiving beta interferon therapy for relapsing multiple sclerosis [American Academy of Neurology 51st annual meeting. Toronto, Ontario, Canada. April 17–24, 1999. Abstracts] Neurology 1999 52 6 Suppl. 2 A135
   Google Scholar
• Broughton A Cosyns JP Jadoul M Thrombotic microangiopathy induced by long-term interferon-β therapy for multiple sclerosis: a case report Clin Nephrol 2011 76 5 396 400 22000560
   PubMed Web of Science ®Google Scholar
• Olea T Díaz-Mancebo R Picazo ML Martínez-Ara J Robles A Selgas R Thrombotic microangiopathy associated with use of interferon-beta Int J Nephrol Renovasc Dis 2012 5 97 100 22815645
   PubMedGoogle Scholar